Daxor Corporation will engage institutional investors at the exclusive Maxim Growth Summit, featuring 40 invited healthcare companies.
Quiver AI Summary
Daxor Corporation, a leader in blood volume measurement technology, announced that its President and CEO, Michael Feldschuh, will engage with institutional investors at the Maxim Growth Summit on October 22-23, 2025, in New York City. The event features a select group of 40 promising healthcare companies and includes keynote speakers such as Larry Kudlow and Christopher Ruddy. During the summit, Feldschuh will hold one-on-one meetings with investors and meet senior analysts from Maxim Group. Daxor aims to address the critical issue of accurately measuring blood volume, which can improve patient care and reduce healthcare costs. The company operates a state-of-the-art manufacturing facility and is focused on expanding its market presence with its patented Blood Volume Analysis technology.
Potential Positives
- Daxor Corporation is highlighted as one of only 40 promising healthcare companies at a prestigious invitation-only summit, which enhances its visibility and credibility among institutional investors.
- The event features high-profile keynote speakers and provides opportunities for direct engagement with institutional investors, potentially leading to increased investment interest.
- Daxor's presentation of its patented Blood Volume Analysis technology addresses a significant issue in healthcare, showcasing its innovative solutions and commitment to improving patient outcomes and efficiencies in care.
- The company's established presence and operational capabilities, including a state-of-the-art manufacturing facility, position it favorably for market expansion in the healthcare sector.
Potential Negatives
- The press release emphasizes the company's need to engage with institutional investors, which may suggest a reliance on external funding or support for growth.
- Forward-looking statements indicate potential risks and uncertainties that could impact the company's future performance, including product development challenges and market acceptance.
- The focus on "tackling healthcare's multi-billion-dollar silent crisis" hints at a significant underlying issue within the industry that may reflect negatively on the company's existing market position.
FAQ
What is the Maxim Growth Summit?
The Maxim Growth Summit is a premier small-cap investor event featuring 40 promising healthcare companies and high-profile speakers in New York City.
Who is representing Daxor Corporation at the summit?
Daxor Corporation is represented by President and CEO Michael Feldschuh, who will engage with institutional investors at the event.
When is the Maxim Growth Summit taking place?
The summit is scheduled for October 22 – 23, 2025, at the Hard Rock Hotel in New York City.
How can investors schedule meetings at the summit?
Institutional investors interested in one-on-one meetings can contact Bret Shapiro, COO of COREIR, for scheduling information.
What technology does Daxor Corporation specialize in?
Daxor Corporation specializes in blood volume measurement technology, providing real-time data that improves patient outcomes in healthcare.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DXR Hedge Fund Activity
We have seen 2 institutional investors add shares of $DXR stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OSAIC HOLDINGS, INC. added 8,750 shares (+inf%) to their portfolio in Q2 2025, for an estimated $85,662
- MORGAN STANLEY added 3,468 shares (+3986.2%) to their portfolio in Q2 2025, for an estimated $33,951
- UBS GROUP AG removed 326 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,191
- RENAISSANCE TECHNOLOGIES LLC removed 100 shares (-0.4%) from their portfolio in Q2 2025, for an estimated $978
- JPMORGAN CHASE & CO added 0 shares (+0.0%) to their portfolio in Q2 2025, for an estimated $0
- SBI SECURITIES CO., LTD. added 0 shares (+0.0%) to their portfolio in Q2 2025, for an estimated $0
- KEYES, STANGE & WOOTEN WEALTH MANAGEMENT, LLC added 0 shares (+0.0%) to their portfolio in Q2 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event
OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City.
Mr. Feldschuh will be available for one-on-one meetings with institutional investors and will also meet with senior Maxim analysts throughout the event.
The conference features high-profile keynote speakers, including Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media), and companies participating are strictly by invitation only from the sponsoring institution.
Investor Meetings:
Institutional investors interested in scheduling a one-on-one meeting should contact the dedicated Investor Relations firm:
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
[email protected]
|
www.coreir.com
For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit .
About Daxor Corporation
Daxor Corporation
(NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com .
Sign up to receive news on Daxor’s innovative technology HERE .
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
[email protected]
|
www.coreir.com
The Maxim conference should highlight that this is an Invitation Only event, for a select group of forty promising health care companies as selected by Maxim, and a premier small-cap investor event
